Is Salesforce’s Agentforce Healthcare Push Quietly Reframing CRM’s Long-Term Competitive Narrative?

• In recent weeks, Viz.ai and Ellipsis Health announced new real-time clinical intelligence and empathetic voice-agent services built on Salesforce’s Agentforce platform, while Salesforce previewed deeper Agentforce 360 integration with Slack and prepared high-profile appearances at the J.P. Morgan Healthcare Conference and the World Economic Forum.
• These moves highlight how Salesforce is turning Agentforce into an ecosystem for sector-specific, agent-based workflows, particularly in healthcare and life sciences, where partners can plug in specialized AI capabilities at scale.
• Against this backdrop, we’ll examine how Salesforce’s expanding Agentforce healthcare partnerships could reshape its investment narrative for long-term-oriented investors.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 23 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

What Is Salesforce's Investment Narrative?

For Salesforce to make sense as a long-term holding, you need to believe its pivot from traditional CRM licenses toward an agentic AI platform can translate its large installed base into durable, higher-value workflows. The recent Viz.ai and Ellipsis Health launches on Agentforce, alongside deeper Slack integration, speak directly to one of the key near-term catalysts: proof that Agentforce can become a real ecosystem in regulated, high-value sectors like healthcare, not just a feature add-on. At the same time, the stock’s sharp pullback and mixed views on AI monetization keep execution risk front and center, especially if autonomous agents from competitors compress demand for user-based licenses faster than Agentforce revenues scale. For now, these healthcare wins feel directionally important, but not yet financially decisive.

However, there is one AI-related risk here that investors cannot afford to ignore. Despite retreating, Salesforce's shares might still be trading 42% above their fair value. Discover the potential downside here.

Exploring Other Perspectives

Across 42 Simply Wall St Community views, fair values span roughly US$241 to over US$435 per share, reflecting sharply different expectations for Agentforce’s impact just as investors weigh pressure on Salesforce’s traditional license model and AI execution risk.

Explore 42 other fair value estimates on Salesforce - why the stock might be worth just $241.03!

Build Your Own Salesforce Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Salesforce research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Salesforce research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Salesforce's overall financial health at a glance.

Ready For A Different Approach?

Our top stock finds are flying under the radar-for now. Get in early:

• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• AI is about to change healthcare. These 109 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com